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The options available for genetic modification of cells of the central nervous system
(CNS) have greatly increased in the last decade. The current panoply of viral and nonviral
vectors provides multifunctional platforms to deliver expression cassettes to many
structures and nuclei. These cassettes can replace defective genes, modify a given
pathway perturbed by diseases, or express proteins that can be selectively activated by
drugs or light to extinguish or excite neurons. This review focuses on the use of canine
adenovirus type 2 (CAV-2) vectors for gene transfer to neurons in the brain, spinal cord,
and peripheral nervous system. We discuss (1) recent advances in vector production, (2)
why CAV-2 vectors preferentially transduce neurons, (3) the mechanism underlying their
widespread distribution via retrograde axonal transport, (4) how CAV-2 vectors have
been used to address structure/function, and (5) their therapeutic applications.
Keywords: adenovirus, CAV-2, coxsackievirus and adenovirus receptor, vectors, neurons, gene therapy, disease
modeling, circuits
UNDERSTANDING STRUCTURE AND FUNCTION BY
MODIFICATION OF CELLS IN THE CENTRAL AND PERIPHERAL
NERVOUS SYSTEM
The human brain contains about 80 billion neurons and trillions of synapses. How a given subset
of neurons influences behavior and cognition will never be completely understood. Nevertheless,
many are trying to use less complex nervous systems to provide a rough blueprint of how
these interactions could influence behavior. Chemical tracers have been used to map circuits and
connections in the brain for decades (Vercelli et al., 2000; Carter and Shieh, 2015). Combining
circuitry data with functional analyses based on the effect of ablation, diseases, infections, or injury
of a given population of neurons also provides insight into the physiological role of some brain
regions (Caeyenberghs et al., 2017). This foundation is now being built upon by the advent of gene
transfer tools that modify cells at the injection site, modify neurons that synapse to those that are
transduced at the injection site (via anterograde transsynaptic transport), or modify neurons that
project into the injection site via retrograde transport of the vector.
Some of the current approaches to understand the function of neuronal subsets exploit
chemo- and optogenetics (Adamantidis et al., 2015; Roth, 2016); they have further refined our
understanding of the mammalian brain. Gene transfer tools that effectively target cells at the
site of injection, as well as those in connected regions, are now available to deliver expression
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 March 2019 | Volume 12 | Article 71
fnmol-12-00071 March 27, 2019 Time: 17:51 # 2
del Rio et al. Prime Time for CAV-2 Vectors
cassettes coding for chemo- and optogenetic proteins that
extinguish or excite neurons. Moreover, the limitations in gene
transfer efficacy are now frequently overcome by using novel and
modified viral vectors.
CLINICAL GENE THERAPY
Gene therapy, i.e., using genetic material as a drug, can transiently
or permanently endow target cells with novel or curative
functions. Gene therapy approaches include, but are not limited
to, gene replacement, gene correction, modifying mRNA stability,
producing alternative gene products that reduce or increase the
efficacy of cellular pathways, or endow cells with novel functions.
The cornerstone in the optimization of in vivo gene transfer
has been the steady improvement of vector design, delivery and
expression kinetics. Viral vectors, which exploit natural uptake
of viruses by cells, can be targeted to specific tissues by diverse
means, including vector choice, vector tropism, the delivery
mechanism, and/or modifying their expression parameters.
The raison d’être for clinical gene therapy targeting the
central nervous system (CNS) is the unquantifiable impact on
the patient and his/her entourage. Second comes the economic
impact of neurodegenerative diseases, which often incurs
costs for decades. Gene therapy to target neurodegeneration
is particularly attractive given the insidious evolution of
CNS diseases that deprive patients of their humanity. Here,
neurodegeneration is defined by conditions that result in the
loss of nerve structure/function that affects cognition, memory,
or motor control. Among the hundreds of neurodegenerative
disorders, considerable attention has been paid to the most
common, in particular Parkinson’s and Alzheimer’s disease.
Nonetheless, therapies for numerous brain diseases are in
pre-clinical or Phase I/II/III stages. Examples include lysosomal
storage disorders (e.g., Sly syndrome; Hunter’s, Batten’s
disease), Huntington’s disease, childhood epilepsies (e.g., Dravet
syndrome), leukodystrophies (e.g., Canavan disease), and
motor control diseases (e.g., amyotrophic lateral sclerosis,
spinocerebellar ataxia) (Piguet et al., 2017).
The major challenges for therapy of neurodegenerative disease
are (1) targeting the correct population of cells (neurons,
astrocytes, and/or microglia) in the desired structure(s), (2) repair
of damaged or deteriorating neurons, (3) maintaining healthy
and/or corrected cells alive in potentially toxic environments,
(4) modifying enough target cells to make a clinical impact,
(5) maintaining therapeutic levels of expression for decades,
and/or (6) endowing the brain with self-repair capabilities.
Self-repair will likely be the Holy Grail of brain gene therapy and
may require the combination of vector-mediated and cell-based
therapy. Indeed, because neurogenesis and astrogenesis continue
throughout our lifetime, they could be combined with gene
transfer for therapeutic approaches.
PANOPLY OF VIRAL VECTORS
The number of viruses, or virus-like particles, that can be
used to develop gene transfer tools is nearly limitless.
Virologists divide vectors either by the type of genome
they contain (single-stranded, double-stranded, segmented,
linear or circular, RNA, or DNA) or by Families (which
is used here). Some of the current vectors are made
from the families Adenoviridae (adenovirus), Retroviridae
(γ-retroviruses, HIV and other lentiviruses), Poxviridae
(pox viruses, vaccinia virus), Togaviridae (α viruses/Semliki
and SV-40), Rhabdoviridae (e.g., rabies virus), Baculoviridae
(baculovirus), Parvoviridae (e.g., adeno-associated viruses),
Herpesviridae (herpes simplex virus, cytomegalovirus,
Epstein–Barr virus), and Hepadnaviridae (hepatitis B virus).
The “virus-to-vector” transition includes using an unmodified
capsid/envelope or altering it by borrowing pieces from
another virus or a cell, or by adding moieties based on
structure-based designs (Gao et al., 2005; Li et al., 2008;
Kremer and Nemerow, 2015).
It is difficult to offer a balanced and critical analysis of the
pros and cons of a viral vector without extensive experience
in its production and in vivo use. While we have first-hand
experience with adeno-associated viruses, γ-retroviruses,
lentiviruses, baculoviruses, and picornaviruses, our expertise
is with generating and using vectors derived from human
and nonhuman adenoviruses. Therefore, here we provide
an update of canine adenovirus type 2 (CAV-2) vectors for
gene transfer to the central and peripheral nervous system
(Junyent and Kremer, 2015).
Adenoviridae
Adenovirus (Ad) infections occur in all human populations
regardless of health standards (Lion, 2014). During repeated
encounters, we generally develop multifaceted humoral and
cellular immune responses (Perreau and Kremer, 2006; Kremer
and Van De Perre, 2015; Mennechet et al., 2015; Eichholz
et al., 2016; Tran et al., 2018). Nevertheless, many human Ad
(HAd) types routinely establish persistent subclinical infection
by mechanisms that are beginning to be identified (Zheng
et al., 2016; Tran et al., 2018). As of 2018, approximately
90 types of Ad have been isolated from humans (Hage
et al., 2017). They are broadly classed into 7 species (A–G),
based on serology, agglutination characteristics, and genome
sequences. Notably, species B and E arose via transmission
from monkeys and great apes (Hoppe et al., 2015). There
are also >300 nonhuman Ads that remain, for the most
part, poorly characterized. The number of nonhuman Ads,
isolated from mammals, reptiles, birds, and fish, will certainly
continue to increase.
As a general rule, all Ads have an approximately 90 nm
diameter, icosahedral, proteinaceous shell (i.e., they are
nonenveloped) that encapsidates a linear, double-stranded
DNA genome of 36 ± 8 kilobase pairs (Kremer and Nemerow,
2015). An increasing number of human and nonhuman
Ads are being tested for their potential as a gene transfer
tools (Duffy et al., 2018). The versatility of Ad genome and
capsid parts allows one to create vectors for either short-term
immunogenic responses (e.g., vaccines) or long-term stable
transgene expression (e.g., for therapy for neurodegenerative
diseases). It is worth noting that very few reports exist describing
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the efficacy of the majority of Ad vectors in the brain, spinal cord,
or peripheral nervous system.
WHY A VECTOR FROM A CANINE
ADENOVIRUS?
It is not surprising that vectors derived from viruses that generate
a multi-faceted immune response in humans are not ideal
candidates for clinical gene transfer. To reduce or circumvent
immune-related drawbacks, numerous strategies have been
used, including the induction of tolerance, immunosuppression,
chemical and genetic modifications of the capsid (Nettelbeck
et al., 2004; Lu et al., 2006; Kreppel and Kochanek, 2008;
Toivonen et al., 2009; Prill et al., 2011). In the early 1990’s,
Klonjkowski et al. (1997) initiated the creation of canine
type 2 (CAdV-2 or more commonly referred to as CAV-2)
vectors (Paillard, 1997). At that time, CAV-2 was the only
nonhuman Ad that had been sequenced and produced as a
vaccine for domestic dogs. An attenuated strain (Manhattan)
of CAV-2 is still used as a vaccine against the more
virulent CAV-1. Only in 1999 was a replication-defective
CAV-2 vector isolated free of wild type CAV-2 (Kremer
et al., 2000). Similar to most HAd vectors, CAV-2 was made
replication-defective by deleting the early region 1 (E1). This
codes for transactivating factors needed to upregulate viral gene
expression and downregulate host cell genes (Horwitz, 1996;
Berk, 2005). Thus, CAV-2 vectors must be propagated in CAV-2
E1-transcomplementing canine cells.
Democratizing CAV-2 Vector
Development – SLiCE and Dice
With I-SceI
The development of replication-defective CAV-2 vectors was
quite a challenge in the mid 1990’s. Similar to the human
cell lines 293 and 911 (Fallaux et al., 1998; Shaw et al., 2002)
that express the human Ad2 E1 region, we generated a canine
cell line that expressed the CAV-2 E1 region, notably because
CAV-2 does not propagate efficiently in human cells. While
generating this canine cell line was relatively straightforward,
selecting a clone for vector production was only possible when
we created the vector.
At the time, recombinant vectors were created through
homologous recombination between two DNA fragments
transfected into transcomplementing cells (Kremer and
Perricaudet, 1995). However, canine cells are notoriously difficult
to transfect with linear, 32 kbp DNA fragments (efficiency
typically < 3%). This precluded the use of homologous
recombination in cells and in turn, vector isolation and
production. The breakthrough in CAV-2 vector generation
occurred when we adapted homologous recombination in
bacteria, which is now routinely used to insert an expression
cassette into a plasmid containing the HAd vectors. This strategy
uses a shuttle plasmid together with a plasmid containing the
Ad genome in recAB+-competent bacteria, typically BJ5183
cells. While homologous recombination in BJ5183 cells works
for CAV-2 vector construction, it was ∼100-fold less efficient
using the equivalent fragment from the human HAd type 5
(HAd5) genome. To circumvent this problem, we now use
seamless ligation cloning extract (SLiCE) strategy (Zhang et al.,
2012). Briefly, SLiCE was initially developed using an extract
of the bacterial strain PPY, which contains λ prophage Red/ET
recombination system, to mediate recombination between a
DNA insert and a linearized vector. It is also possible to generate
SLiCE extracts with the commonly-used bacterial strains DH5a,
DH10b, XL10-gold or SURE2 (Motohashi, 2015). We find that
SLiCE is an efficient, simple, inexpensive, and rapid method for
cloning expression cassettes into a 32 kbp plasmid containing
the CAV-2 genome. Expression cassettes are inserted directly
into either the E1, the E3 (which codes for proteins involved
in limiting the immune response to the infected cells and
is dispensable for vector use), or the E1 and E3 regions in
less than 1 week. Notably, SLiCE eliminates the need for the
shuttle plasmid used in the commercially available “AdEasy
system” (Figure 1).
The second step is generating viral vectors from the plasmid
that contains the recombinant vector genome. As mentioned
above, canine cells are poorly transfected with linear 32 kbp DNA
fragments. To circumvent this, we adapted another technique
based on the use of I-SceI activity in DKE1 cells (Ibanes
and Kremer, 2013). We generated DKSce1 cells constitutively
expressing I-SceI fused to the hormone binding domain of the
oestrogen receptor (ER). I-SceI is a yeast endonuclease that
recognizes an 18 bp sequence (Choulika et al., 1994). In the
absence of the ER ligand 4-OH tamoxifen, the I-SceI-ER protein
remains cytoplasmic, thereby avoiding potential damage to the
cellular genome. The 18 bp I-SceI recognition site was inserted
flanking the CAV-2 genome in the plasmid backbone, and
freshly prepared supercoiled plasmid DNA increases transfection
efficacy to > 50% in DKSce1 cells. 4-OH-tamoxifen-mediated
nuclear translocation of the I-SceI-ER allows excision of the
vector genome from the circular plasmid (Ibanes and Kremer,
2013). Restriction by I-SceI is a prerequisite because an Ad
genome needs two free ends to initiate replication. This
technical advance increased CAV-2 vector generation from
plasmid DNA by <1,000-fold. The combination of SLiCE
and I-SceI allows us to generate, under optimal conditions,
a CAV-2 vector deleted in the E1 and/or E3 regions in
17 days (Figure 1).
The Production and Advantages of
Helper-Dependent CAV-2 Vectors
E1/E3-deleted CAV-2 vectors have numerous advantages: a
cloning capacity of >7 kbp; can be purified in high titers (>1013
physical particles/ml) in a basic research laboratory; the highest
ratio of infectious units/physical particles reported for any viral
vector (>1:3) (Kremer et al., 2000); weak recognition by both
the adaptive immune response in rats and pre-existing immunity
in humans (Perreau and Kremer, 2005, Kremer, 2006; Perreau
et al., 2007a,b). However, larger expression cassettes are needed
in some cases. In these cases, helper-dependent (HD) CAV-2
vectors (Soudais et al., 2004) are useful. HD vectors lack all
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 March 2019 | Volume 12 | Article 71
fnmol-12-00071 March 27, 2019 Time: 17:51 # 4
del Rio et al. Prime Time for CAV-2 Vectors
FIGURE 1 | CAV-2 vector production. A schematic representation of the steps and timeline for (A) cloning using SLiCE, (B) vector generation from plasmid using
SceI-expressing cells, and (C) vector amplification in cell factories, purification and quality control (QC). GoI, gene of interest.
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regions coding for viral proteins but retain the inverted terminal
repeats (ITRs) and packaging signal (ψ) (Brunetti-Pierri and Ng,
2016). The 198 bp CAV-2 ITRs are needed for DNA polymerase
to initiate genome replication. The 150 bp CAV-2 ψ (Soudais
et al., 2001a) is bound by proteins that initiate the insertion
of the linear genome into the capsid (Alba et al., 2011). HD
vectors, also called high-capacity (HC), gutted, or gutless, can
accommodate DNA inserts of up to 36 kbp. In most tissues,
HD vectors increased the duration of transgene expression
(Morral et al., 1998; Amalfitano and Parks, 2002; Kreppel and
Kochanek, 2004; Brunetti-Pierri et al., 2007; Ariza et al., 2014;
Cubizolle et al., 2014; Serratrice et al., 2014; Brunetti-Pierri
and Ng, 2016). Given their characteristics, these vectors further
improve in vivo safety and efficacy for long-term treatment of
neurodegenerative diseases.
To generate HD vectors, cloning can be performed in
E. coli via classic digestion/ligations, homologous recombination,
or via SLiCE. Whether the 95–105% genome size limit
for HAd5 vectors (i.e., minimum genome size of ∼34 kbp
and a maximum of 38 kbp) applies to the 32 kbp CAV-2
genome and capsid is unknown. As in the case of E1-deleted
CAV-2 vector generation, the HD genome is transfected into
DKE1 cells that are co-infected with an E1-deleted “helper”
vector, which provides the viral proteins in trans during
the 36 h propagation cycle. While both HD and helper
genomes replicate, helper genome packaging is prevented by
flanking its ψ with the 34 bp lox sequences together with
expression of Cre recombinase by the cells or the helper vector
(Kochanek et al., 1996; Morsy et al., 1998). Ipso facto, Cre
excises the helper’s ψ, leading to preferential packaging of the
HD vector genome.
Unfortunately, constitutive expression of Cre recombinase
in DKE1 cells (DKCre cells) decreases cell viability, protein
expression by the E1 region, and production of HD CAV-2
vectors (Fernandes et al., 2015a; Simão et al., 2016).
Multiple amplification steps are needed to produce HD
CAV-2 vectors, which also hampers robust production and
in turn the availability of high quality preps. This led us
to analyze the progression of the HD vector propagation
cycle (Fernandes et al., 2015b). Paulo Fernandes found
that the helper genome replicates faster during HD vector
production compared to E1-deleted vectors alone. This is
mirrored by increased expression of the CAV-2 polymerase,
pre-terminal protein, and structural proteins. While genome
packaging resembles that of E1-deleted vectors, more
immature capsids are generated during HD production.
This leads to a fourfold increase in the physical-to-infectious
particles ratio, as well as augmented autophagy and cell
death, which further compromises productivity. One
potential approach to improve HD CAV-2 production is
a helper vector with a floxed ψ, which also expresses a
transcriptionally-regulated CreERT2 cassette (Gonzalez-
Aparicio et al., 2011). This vector would allow the use
of DKSceI cells for HD CAV-2 vector production and
potentially increase both production and the infectious
units/physical particle ratio.
CAV-2 PREFERENTIALLY TRANSDUCES
NEURONS DUE TO CAR EXPRESSION
The tropism of a virus is usually associated with the clinical
symptoms. However, the tropism of viral vectors does not
a priori mimic that of their virus of origin. Similar to
the tropism of HAd5, CAV-2 is thought to preferentially
infect the upper respiratory track in Canidae and Ursidae.
In dogs, CAV-2 causes a mild disease called “kennel cough”
(Wright et al., 1972). In the case of a vector, cellular and
tissue targets are a function of multiple factors: (1) the
mode of injection (e.g., intravenous, subcutaneous, intradermal,
intramuscular, intranasal, intracerebral, intrathecal. . .), (2) host
physiology (e.g., when the blood brain barrier closes), (3) capsid
modifications, (4) interaction with extracellular components
(5) fluid flow dynamics, and other factors. Upon intracerebral
and intramuscular injection, CAV-2 vectors preferentially
transduce neurons (Soudais et al., 2001b). When a CAV-2
vector expressing GFP (CAVGFP) was placed in the olfactory
cavity, which is predominantly lined with columnar epithelial
cells, sensory olfactory neurons were preferentially transduced.
Injection in the hindleg muscle in newborn mice led to
poor transduction of myofibers but a surprising specificity for
the innervating motoneurons via retrograde axonal transport
(Soudais et al., 2001b, 2004; Salinas et al., 2017). Similarly,
following injection into the highly innervated diaphragm, few
muscle cells were transduced but a significant number of
neuromuscular junctions were GFP+, again demonstrating a
preference for motoneurons and axonal retrograde transport of
CAV-2 (Soudais et al., 2001b). When injected into the rodent
brain parenchyma, CAV-2 vectors preferentially transduced
neurons at the site of injection, as well as the neurons that
project into this area (see Box 1). Following injection in the
striatum, dopaminergic neurons of the substantia nigra pars
compacta (SNpc), thalamic neurons, and cortical neurons (layer
IV) of the ipsilateral and contralateral neocortex are transduced
(Soudais et al., 2001b; Hnasko et al., 2005; Kremer, 2005;
Bru et al., 2010).
We also injected a HD CAV-2 vector expressing GFP
(HD-GFP) in the Microcebus murinus caudate nucleus (Mestre-
Francés et al., 2018). M. murinus, commonly called the gray
mouse lemur, is small nocturnal primate from Madagascar,
whose brain structure and organization are comparable to
that of the human brain. M. murinus have been bred in
captivity since the 1960s, with lifespan of ≥ 10 years. This
primate is increasingly used to study aging, Alzheimer’s disease
(including amyloid-β vaccination) (Trouche et al., 2009), and
identification of cognitive deficits (Kraska et al., 2009; Trouche
et al., 2010). Due to captive breeding programs, M. murinus
is one of the few primates allowed by current European
regulations for research. After HD-GFP injection in the striatum,
GFP+ somata and processes were found at the injection site,
throughout the frontal and occipital cortex in both hemispheres,
in the SNpc of both hemispheres, and in the ipsilateral
basal nuclei of Meynert. The dense GFP signal surrounding
the injection site was consistent with transduction of striatal
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BOX 1 | Recent examples of CAV-2 vector use.
• The Adan lab used the same tools to identify the ventral tegmental area (VTA) to nucleus accumbens pathway. In some cases, this approach can circumvent
the need to implement glass fibers for optogenetic stimulation and complements the use of transgenic Cre mice (Boender et al., 2014).
• Using a similar approach, Carter et al. (2013) demonstrated that the neural circuit from the parabrachial nucleus to the central nucleus of the amygdala is
involved in the suppression of appetite.
• Lerner et al. (2015) used CAV-2 vectors to identify two distinct nigrostriatal DA circuits with differing in inputs, outputs, biophysical properties, and
environmental information representations. Both circuits independently control information representations streaming through SNpc and each provides a
generalizable framework for brain-wide mapping of diverse populations of neurons defined by multiple independent types of features (Lerner et al., 2015).
• The Maren lab showed that medial prefrontal cortex-thalamic nucleus reuniens circuits inhibit the expression of Pavlovian fear memories in rats, a function that
influences adaptive emotional regulation (Ramanathan et al., 2018).
• By using CAV-2 vectors and DREADD-mediated inhibition of laterodorsal tegmentum excitatory cholinergic inputs to the VTA, the Barik lab in Marseilles
characterized a neuro-circuitry implicated in depressive-like disorders (Fernandez et al., 2018).
• The Huberman lab explored how our internal state is merged with our visual perception of an impending threat to drive an adaptive behavioral response. They
showed that the nucleus reuniens, nuclei of the ventral midline thalamus, and the xiphoid nucleus (Xi) are implicated in controlling behavioral responses to visual
threats (Salay et al., 2018).
• In Bordeaux, Senn et al. (2014) showed using CAV-2 vectors and optogenetics that dorsal medial prefrontal cortex that projects to the lateral and ventrolateral
periaqueductal gray circuits are necessary for discriminating a previously threatening context from a neutral context.
• Using CAV-2 vectors and chemogenetic silencing of the lateral hypothalamus-lateral habenula pathway, the Mameli lab showed that aversive stimuli such as
foot-shocks drive hypothalamus-to-habenula excitation to promote escape behavior in mice (Lecca et al., 2017).
• The Stuber lab showed that in addition to intra-cortical connectivity, prefrontal cortical projection neurons innervate subcortical structures that contribute to
reward-seeking behaviors. Using CAV-2 retrograde transport for bidirectional optogenetic manipulation of these neurons allowed them to demonstrate that
stimulation of corticostriatal neurons promotes conditioned reward-seeking behavior after learning. By contrast, activity in corticothalamic neurons suppresses
both the acquisition and expression of conditioned reward seeking (Otis et al., 2017).
• The locus coeruleus (LC) projects to almost the entire neuro-axis and plays a role in learning and memory, pain, motivation, strategic behavior, and arousal. The
LC is the principal noradrenergic nucleus in the CNS and is the main source of noradrenergic innervation to the spinal dorsal horn, forming part of an analgesic
circuit (Li et al., 2016; Hirschberg et al., 2017). It was unclear whether the LC acts functionally as a single global effector or as discrete modules. Specifically,
while spinal-projections from LC neurons can exert analgesic actions, it was unknown whether they can act independently of ascending LC projections. The
Pickering lab unraveled this dichotomy using CAV-2 uptake at axon terminals and a pharmaco-selective actuator module (PSAM) to selectively target LC
neurons with spinal (LC→SC) or prefrontal cortex (LC→PFC) projections (Li et al., 2016; Hirschberg et al., 2017). Activation of the LC→SC module produced
robust, lateralized anti-nociception while activation of LC→PFC produced aversion. In a neuropathic pain model, LC→SC activation reduced hind-limb
sensitization and induced conditioned place preference. By contrast, activation of LC→PFC exacerbated spontaneous pain, produced aversion and increased
anxiety-like behavior.
• Still in the LC, the Johansen lab examined how the circuit and neural-coding features of this neuromodulatory system regulates aversive emotional learning and
behavioral flexibility in rats. They described a modular organization containing distinct neural projection patterns and coding properties for flexible specification
of opposing behavioral learning states. An amygdala-projecting group promoted aversive learning, while a medial prefrontal cortex-projecting group
extinguished aversive responses (Uematsu et al., 2017).
• The Nir lab examined how LC activity modulates sensory-evoked awakenings, testing whether reduced LC activity mediates sensory disconnection occurring
in sleep. Optogenetic LC excitation using CAV-2-mediated ChR2 modulated arousal as shown by sleep-wake transitions, EEG desynchronization, and pupil
dilation. Sounds presented on a background of weaker LC excitation (not awakening by itself) led animals to wake up frequently. Next, Hayat et al. (2019)
silenced LC activity using a CAV-2 vector harboring a soma-targeted anion-conducting channelrhodopsin (stGtACR2) under the control of the PRS promoter
and showed that it effectively silences LC activity and constricts pupils. Brief LC silencing around auditory stimulation reduced sound-evoked awakenings,
showing that LC activity is both necessary and sufficient for modulating sensory-evoked arousal threshold (Hayat et al., 2019).
• Using CAV-2 vectors, targeted lesion, optogenetic, and chemogenetic stimulation of central amygdala of mice, the de Araujo lab identified coordinated circuits
emanating from the central amygdala that control the efficiency of prey capture and the ability to deliver fatal bites to prey. Coordinated control of cervical and
mandibular musculatures was mediated by a central amygdala projection to the reticular formation in the brainstem. By contrast, prey pursuit was mediated by
projections to the midbrain periaqueductal gray matter (Han et al., 2017). The de Araujo lab also showed how the gut-brain neuronal circuitry regulates of
motivational and emotional states. Using CAV-2 vector to infect gut-innervating vagal sensory neurons and optogenetics they found that right, but not left,
vagal sensory ganglion activation sustained self-stimulation behavior, conditioned flavor and place preferences, and induced dopamine release from SNpc cells
(Han et al., 2018).
• Asokan et al. (2018) examined how the layer 5 cortical neurons coordinate integrative auditory processing and adaptive behaviors. Using CAV-2 vectors they
showed that auditory corticofugal neurons that innervate the inferior colliculus have widespread targets throughout the forebrain.
• The Tye lab has used CAV-2 vectors to identify and characterize several pathways (Allsop et al., 2014; Tye, 2014; Namburi et al., 2015; Beyeler et al., 2016;
Vander Weele et al., 2018). These pathways include the medial prefrontal cortex projections to the dorsal periaqueductal gray (Vander Weele et al., 2018); the
basolateral amygdala neurons during the retrieval of associative memories via synapse in the nucleus accumbens, the central amygdala, or ventral
hippocampus (Namburi et al., 2015; Beyeler et al., 2016).
• At the Friedrich Miescher Institute for Biomedical Research in Basel, the Arber lab characterized motor collateral organization between the spinal cord and
neurons in the brainstem. Pivetta et al. revealed a widespread and diverse network of spinal dual-axon neurons, with coincident input to forelimb motor
neurons and the lateral reticular nucleus in the brainstem (Pivetta et al., 2014; Ruder et al., 2016). The Lüthi lab functionally characterized the connections of
basal nucleus of the amygdala – medial prefrontal cortex (Vogel et al., 2016) and in particular the prelimbic and infralimbic subdivisions in fear
generation and extinction.
• The Grinevich lab used CAV-2 vectors to separate magno- versus parvocellular oxytocin neurons and hypothalamic paraventricular neurons projecting to the
supraoptic nuclei, and spinal cord deep laminae of L5 projections to cell bodies of oxytocin neurons in the paraventricular nuclei and their axonal projections in
close proximity to somas and dendrites of magnocellular oxytocin neurons of the supraoptic nuclei (Eliava et al., 2016).
• The Arenkiel lab showed that the arcuate nucleus, receives cholinergic, and noncholinergic diagonal band of Broca projections to regulate appetite
(Herman et al., 2016).
• The Chester lab used the retrograde transport of CAV-2 from the central nucleus of the amygdala and the dorsal reticular formation in the medulla to the
parabrachial nucleus to help characterize a brainstem circuit that controls escape responses to select noxious stimuli (Barik et al., 2018).
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neurons and afferent axons from other brain areas. In some
animals, the vector leaked into the ventricles/cerebral spinal
fluid and transduced SOX2+ cells lining the lateral ventricles.
It is unknown if these SOX2+ cells were equivalent to the
neural precursor cells infected by CAV-2 in the mouse brain
(Salinas et al., 2017).
In the M. murinus brain, the total number of GFP+
neurons at 6 months was equivalent to that at 2 weeks,
demonstrating that the vectors led to long-term expression
of a potentially immunogenic protein (GFP) (Mestre-Francés
et al., 2018). These authors also quantified TH+/GFP+ neurons
in the SNpc following vector deposit at a single coordinate
in the caudate nucleus, and found a transduction efficacy of
approximately 70% in the 3,000 TH+ neurons/hemisphere.
Thus, these data demonstrate that in the primate brain
CAV-2 vectors preferentially transduce neurons, are transported
to afferent structures, and allow stable expression of a
foreign protein.
CAV-2 IS RETROGRADELY TRANSPORT
(FROM THE AXON TIP TO THE SOMA)
As in the rodent brain (Zussy et al., 2016), expression of the
coxsackievirus and adenovirus receptor (CAR) is restricted to
neurons in the M. murinus brain parenchyma (Salinas et al.,
2013; Mestre-Francés et al., 2018). While the transduction profile
in the M. murinus brain is similar to that of the rodent brain,
efficacy is globally better. CAV-2 infects neurons by binding to
CAR at axon terminals (Salinas et al., 2009, 2010), however,
the density and distribution of CAR along the surface of axons
has not been extensively characterized. In most regions of the
mouse brain, anti-CAR staining appears as small puncta along
axons and dendrites (Zussy et al., 2016). Moreover, CAR is
found in the presynapse fraction of synaptosome preparations
from adult mouse, M. murinus and human brains (Zussy et al.,
2016). While CAV-2 can efficiently enter a neuron via presynaptic
termini, other entry sites are possible, but the efficacy is unknown
(Schwarz and Luo, 2015).
Another aspect about CAV-2 vectors is that the preference
for neuronal subtypes is not fully characterized. While CAV-2
infects many classes of neurons, such as motor, sensory,
parasympathetic, GABAergic, cholinergic, norepinephrine
(NE), and dopamine (DA) neurons (Figure 2 and Box 1;
Hnasko et al., 2006; Salinas et al., 2009; Beier et al., 2015; Schwarz
et al., 2015; Li et al., 2016; Uematsu et al., 2017), some neurons
may not express CAR and are therefore transduced less efficiently
if at all. A potential example of this is the comparison of CAV-2
vectors to an engineered AAV vector (AAV-retro) selected for its
capacity for in vivo retrograde transport from the mouse basal
pontine nuclei (Tervo et al., 2016). While the study provided no
information with respect to dose, volume, number of animals,
or controls, they concluded that CAV-2 vectors poorly infected
these neurons and therefore did not induce significant cortical
expression of GFP in Rosa26-LSL-H2B-eGFP mice after injection
in the basal pontine nuclei.
Axonal transport is essential for neuronal homeostasis,
as its impairment can be linked with neurodegenerative
disorders (Hinckelmann et al., 2013; Millecamps and Julien,
2013; Gibbs et al., 2015; Grosch et al., 2016). Some viruses,
including rabies, herpes simplex type I, and poliovirus,
as well as tetanus toxin, use axonal transport to access
the soma of neurons in the CNS (Salinas et al., 2010).
Live-cell imaging and cell biology approaches allowed us
to characterize the mechanisms regulating CAV-2 entry
and transport in primary rodent motor neurons (Salinas
et al., 2009; Henaff et al., 2011; Simão et al., 2015). CAV-2
trafficking occurs in pH neutral endosomes, which allows
long-range transport in an environment that precludes
pH-induced conformational changes of the capsid and
endosomal escape. Interestingly, tetanus toxin and other
viruses, along with neurotropic factors and their receptors, are
transported in these endosomal structures (Salinas et al., 2010;
Schmieg et al., 2014).
HOW CAV-2 HAS BEEN USED FOR MPS
THERAPY AND TO MODEL
NEURODEGENERATIVE DISORDERS
Treating Mucopolysaccharidoses
Type IIIA and VII
Mucopolysaccharidoses (MPSs) are a group of rare, autosomal
recessive disorders caused by deficiencies in the catabolism
of glycosaminoglycans (GAGs) (Mehta and Winchester, 2012).
FIGURE 2 | LC transduction. While working with the laboratories of Liqun Luo [100], Tony Pickering (Li et al., 2016; Hirschberg et al., 2017), and Johan Johansen
(Uematsu et al., 2017), we have used the retrograde transport of CAV-2 vectors to characterize the connections and functions of the LC. Here we present some of
the results showing LC connectivity as determined by CAV-2 retrograde transport. The green syringe shows where CAVGFP was injected. The kidney shaped blow
up represents the LC and green dots are GFP positive soma.
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Several MPSs are associated with neuropathologies presenting
variable clinical symptoms (Eto and Ohashi, 2002). For MPS
brain therapy, the majority of cells do not need to be
transduced by a therapeutic vector due to the phenomenon
of cross-correction (Neufeld, 2011). Nevertheless, transduced
cells must be dispersed throughout the brain to generate
local factories that secrete enzymes. Thus, multiple injections
throughout the brain must be combined with a vector that
is capable of widespread brain distribution. For these reasons,
CAV-2 vectors are ideal candidates for gene transfer. Indeed,
CAV-2 vectors have been tested for their ability to improve
neuropathological changes associated with MPS IIIA and MPS
VII (Lau et al., 2010; Ariza et al., 2014; Cubizolle et al., 2014;
Serratrice et al., 2014).
Neonatal administration of CAV-2 vectors harboring a
N-sulfoglucosamine sulfohydrolase expression cassette produced
both dose-dependent and widespread transgene expression
that persisted for at least 20 weeks and prevented memory
and learning deficits in mice (Lau et al., 2010). By contrast,
introduction of the same vectors in the thalamus and ventricles
of adult MPS IIIA mice resulted in limited duration of
N-sulfoglucosamine sulfohydrolase expression (Lau et al., 2012).
There are several potential reasons for this: the adult MPS
IIIA mouse brain is primed by damage-associated molecular
pattern molecules (Yang et al., 2017) and GAGs that induce
chronic inflammation and likely “trained immunity” (Mehta and
Winchester, 2012; Saeed et al., 2014; Netea et al., 2016; Netea and
van der Meer, 2017). This inflammatory-primed environment
would render vector injection less benign and the detection of
a pathogen-associated molecule, like the double-stranded DNA
genome of a vector in the cytoplasm, would likely amplify an
immune response.
This hypothesis is supported by the work from Ariza et al.
(2014), who also showed that transient immune suppression
dramatically improves the duration of transgene expression in
the MPS VII mouse brain. MPS VII is caused by deficient
ß-glucuronidase activity, which results in the partial degradation
of chondroitin sulfate, dermatan sulfate, heparan sulfate, and
gangliosides (Ray et al., 1999; Heuer et al., 2001). We
demonstrated that a CAV-2 vector containing a ß-glucuronidase
expression cassette restores global ß-glucuronidase activity,
reduces GAG accumulation, and corrects both the enlarged
storage vesicle and irregular lysosome morphology in the brains
of MPS VII mice and the ∼200-fold larger MPS VII dog
(beagle) brain (Ariza et al., 2014; Cubizolle et al., 2014).
Equally relevant, this approach improved cognitive functions
of MPS VII mice (Ariza et al., 2014). In contrast to a
study using AAV vectors for MPS I/III therapy (Ellinwood
et al., 2011), transient immunosuppression was sufficient
when using HD CAV-2.
Using CAV-2 Vectors to Model
Parkinson’s Disease in Nonhuman
Primates
Vector-mediated gene transfer can also be used to better
understand neurodegenerative diseases. Due to the efficient
infection of DA neurons in the SNpc following injection
in the striatum (Soudais et al., 2001b, 2004; Hnasko et al.,
2005, 2006; Mestre-Francés et al., 2018), Parkinson’s disease
modeling is an attractive target for CAV-2 vectors. Like
the NE neurons in the locus coeruleus, CAV-2 vectors can
transduced > 90% of the rat or 70% of M. murinus DA
neurons in the SNpc following injection into striatum (Soudais
et al., 2001b, 2004; Mestre-Francés et al., 2018). Vector-mediated
gene transfer can complement transgenic rodents and/or
drug-induced disease models that have been invaluable, yet
imperfect, for unraveling the mechanism of numerous brain
and systemic disorders. The general consensus is that the lack
of robust Parkinson’s disease animals reproducing its complex
characteristics hampers progress in both the understanding
of pathogenic mechanisms and identification of therapies.
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced
Parkinson’s disease in primates is often used to test the efficacy
of therapeutic approaches. However, MPTP induces acute and
toxic injury to DA cells and poorly mimics the progressive
course of Parkinson’s disease. In addition, MPTP injections
do not lead to the definitive Parkinson’s disease pathological
hallmarks of α-synuclein (α-syn) aggregates and Lewy body
formation (Beal, 2010). One approach is to express LRRK2G2019S,
the most common dominant-negative mutation in patients with
familiar and sporadic Parkinson’s disease. The LRRK2 cDNA
is ∼7.5 kbp, i.e., too large for AAV and lentivirus vectors.
By contrast, the LRRK2 cDNA is readily cloned into a HD
CAV-2 or herpes virus vector (Lee et al., 2010). Injection
of CAV-LRRK2G2019S into the brain of M. murinus induced
Parkinson’s disease-like motor symptoms, swelling and loss of
neurites, dystrophic neurons, and reduced tyrosine hydroxylase
immunoreactivity in the putamen (Mestre-Francés et al., 2018;
Lasbleiz et al., 2019).
NETWORKS, CIRCUITS, PAIN,
AND BEHAVIOR
Networks: Tracing the Relationship
Between Input and Output (TRIO)
Deciphering how neural circuits are anatomically organized
with respect to input and output connections is instrumental
in understanding how the brain processes information. TRIO
is a technique to map input–output connections in a selected
region (Beier et al., 2015; Schwarz et al., 2015). To trace neural
pathways, TRIO uses the combinatorial power of CAV-2, AAV,
and rabies virus vectors (Figure 3). Briefly, an AAV2 vector,
which preferentially infects cells at the site of injection, contains
genes for an engineered receptor for a pseudo-typed rabies virus
and a fluorescent protein (e.g., mCherry). The open reading
frames for the receptor and mCherry in the AAV vector are
in reverse orientation (3′–5′) and flanked by double-inverted
oriented (DIO) lox sequences (i.e., a DIO cassette). Thus, an
AAV-infected neuron must contain Cre recombinase for the
receptor and mCherry to be expressed. Cre is delivered by
CAVCre, which is injected at a site that may contain axonal
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FIGURE 3 | TRIO: tracing the relationship between input and output neural circuits. Three viral vectors are used. CAV-2, a nonenveloped capsid containing an
∼32 kbp double-stranded DNA genome; AAV, a nonenveloped capsid containing a single-stranded DNA genome of ∼5,000 nucleotides: and a rabies virus, an
enveloped particle containing negative single-stranded RNA genome. TRIO takes advantage of the retrograde transport capacity of CAV-2 vectors, the local
transduction of neurons without significant retrograde transport of the AAV vector, and the transsynaptic transport of rabies vector. In this schema, CAVCre (in blue)
and AAV-TVA-mCherry (in red), containing the receptor for the rabies virus (TVA) and mCherry flanked by double inverted lox sequences, are injected in the
respective locations (shaded blue for CAVCre, locus X/unshaded oval for the AAV). AAV vectors need ∼2 weeks to generate the second strand of their genome. It is
then that Cre expression induces the expression the rabies virus receptor by flipping the expression cassette to “on.” All mCherry+ cells have been transduced by
CAVCre and AAV-TVA-mCherry, which identifies the output connection of locus X. Rbv-GFP is then injected at the same coordinates of the AAV injections (locus X
unshaded oval). Only mCherry positive cells, which also express TVA for the pseudo-typed rabies vector can be transduced, therefore mCherry+ and GFP+ cells
have been transduced by all three vectors. Rbv-GFP then undergoes a round of replication, and new particles are transported into neurons that synapse to the
infected cell. GFP+/mCherry− cells identify input regions.
projection of the neurons infected by the AAV vector. This
combination allows one to identify the output of the neurons
in the locus/region/structure targeted by the AAV injections,
because these cells become mCherry+. To identify which cells
synapse to the AAV and CAVCre infected neurons (which now
express the receptor for the pseudo-typed rabies virus also), one
injects the rabies vector that harbors a GFP expression cassette.
Here, infection is restricted to the subset of cells expressing its
receptor, i.e., only cells infected with both CAVCre and AAV
vectors. The rabies vector turns these cells yellow (mCherry +
GFP = yellow), and is capable of a single replication cycle,
transcytosis, and retrograde transport to synapsing neurons.
Cre+/mCherry+/GFP+ cells are infected by the three vectors,
while GFP+ cells synapse to the neurons at the injection
site. TRIO, as well as a more complex version called cTRIO
(Beier et al., 2015; Schwarz et al., 2015), allows identification
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FIGURE 4 | Transcriptional pathways affected by HD-CAV-2 in human neuron in vitro and M. murinus neurons in vivo. (A,B) Functional transcriptional signature of
HD-CAV-2 in classic 2D cultures (A) or 3D bioreactor cultures (B) from differentiated human midbrain progenitor cells obtained by in silico G-profiler analysis of
microarray data on RNA extracted at 5 days post-vector addition. (C) Meta-analysis of functional signature of HD-CAV-2 in 2D or 3D cultures on RNA extracted at
5 days post-vector addition and of RNA extracted from M. murinus striatum at 24 h and 28 days after HD-CAV-2 stereotaxic injection. Green – DNA metabolism
related functions; red – microtubule related processes; yellow – immune response related processes; blue – cell division/organization related functions.
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of the relationship between input and output circuits, thereby
improving our understanding of normal brain function and
potentially diseases like depression, addiction, and schizophrenia.
Functional Characterization of Circuits
When an anatomical circuit has been identified and/or
characterized it can be targeted for functional analyses.
Previously, the complexity of neural anatomy, i.e., many
thousands of neurons synapsing with thousands of other
neurons, made identifying the involvement of a given neuronal
pathway in a specific behavior a daunting challenge. Combining
optogenetics (e.g., channelrhodopsins, a family of proteins
that function as light-gated ion channels) (Adamantidis
et al., 2015), DREADDs (designer receptor exclusively
activated by designer drugs) (Roth, 2016) and retrograde
vector transport allows specific targeting and manipulation
of neural pathways. In turn, these tools have improved
our understanding of how the activity of specific neuronal
pathways can act as determinants of behavior (Sara, 2009;
Takeuchi et al., 2016). Often, optogenetic and DREADD
technologies are used in knock-in mice expressing Cre,
which limits their applicability. As suggested by Nair et al.
(2013), using these technologies together with Cre-expressing
viral vectors, e.g., CAV-2, provides a way to target specific
neural pathways with cellular resolution. These options
include (1) combining CAVCre and a second viral vector
containing a Cre-inducible (DIO) DREADD/channelrhodopsin
expression cassette, (2) using CAVCre in knock-in mice
with a DIO DREADD/channelrhodopsin expression
cassette, or (3) injecting CAVFlexFlp vector harboring a
Flippase-inducible Ce expression cassette into a knock-
in mouse expressing DIO DREADD/channelrhodopsin
in a subset of neurons (e.g., under transcriptional
control) (Beier et al., 2015; Schwarz et al., 2015). Any
of these approaches would allow the activation of a
group of neurons in one area of the nervous system that
innervate a distal area.
COULD CAV-2 VECTOR INFECTION
PERTURB NEURON FUNCTION?
One way to measure the influence of viral vectors on tissue
homeostasis is to characterize the changes in the transcriptional
signature. This approach helps dissect the interplay between
vectors and host-specific cells, predict vector impact, and identify
vector-specific responses (Piersanti et al., 2013, 2015). Global
transcriptional analyses were used to analyze the impact of
E1/E3-deleted and HD vectors on human cells (Simão et al.,
2016). DNA chips were used to assess the transcriptional changes
in lung fibroblasts induced by HAd5 compared to AAV5 particles
(Stilwell et al., 2003; Stilwell and Samulski, 2004). Furthermore,
transcriptome analyses corroborate in vivo data indicating that
AAVs have a quantifiably different effect on host cells compared
HAds. Such analyses also showed that the activation of the innate
response by group C HAdVs is affected by HAd-factor X (FX)
complexes (Doronin et al., 2012).
BOX 2 | Take home messages.
• CAV-2 vectors preferentially transduce neurons in the rodent, canine,
and primate brain due to the neuronal expression of CAR in the
brain parenchyma.
• Uptake at axons and delivery to the somata (retrograde transport) occurs
via pH neutral multitasking endosomal vesicles.
• Previously cumbersome, CAV-2 vector cloning, generation and
production are now straightforward due to SLiCE and I-Sce1-ER
expression in transcomplementing cells.
• The payload/cloning capacity of E1/E3-deleted CAV-2 vectors is >7 kbp.
• Transgene expression from E1/E3-deleted CAV-2 vectors is stable for at
least 6 months in rats.
• The payload/cloning capacity of HD CAV-2 vectors is > 30 kbp.
• Transgene expression from HD CAV-2 vectors is stable for at least
12 months in rodents and in primates.
•When E1/E3-deleted CAV-2 vectors transduce neural precursor or neural
stem cells, the cells still efficiently integrate into the existing circuits.
• HD CAV-2 vectors do not significantly perturb the transcriptome of
human NPCs or neurons in the NHP brain.
• CAV-2 vectors have been used to: treat mucopolysaccharidoses in the
mouse and dog, model Parkinson’s disease in NHPs by expressing a
hyperactive kinase form of LRRK2, and used by numerous groups to
understand and explore neuronal networks.
Given the potential of HD CAV-2, DNA chips were used
to characterize the influence of HD CAV-2, HD HAd5,
and lentivirus vectors on transcription in human midbrain
neuroprogenitor cells differentiated into dopaminergic neurons
and propagated in 2D cultures (Piersanti et al., 2013, 2015;
Mestre-Francés et al., 2018). The three viral vectors differentially
affected the transcriptome, activating pro-survival genes and
slightly altering neuron morphogenesis. While HD CAV-2
did not negatively affect neuronal development, it did induce
an innate immune response. HD CAV-2 induced a lower
transcriptional response when compared to HD HAd5 and
lentivirus vectors. The HD CAV-2 transcriptional signature
was further refined using 3D human neurospheres. These
neurospheres were generated from midbrain progenitors and
display multiple characteristics of human brain (Brito et al.,
2012; Gualda et al., 2014; Simão et al., 2015). The effect of
HD CAV-2 on the transcriptome in neurospheres was similar
to that observed in the 2D culture system, with the notable
addition of centromeric- and microtubule-related genes in 3D
cultures. Finally, DNA chips were used to analyze transcriptional
alterations in brain tissue of M. murinus following stereotaxic
injection of the HD-CAV-2 into the caudate nucleus. The
vector induced a modest modulation of genes involved in the
immune response, intracellular trafficking and transcriptional
regulation. Comparing the data sets from the three model
systems (2D and 3D midbrain cultures and M. murinus
brains) reveals that HD CAV-2 specifically modulates genes
related to the cell cycle, microtubule organization and DNA
metabolism (Figure 4). We hypothesize that the effects on
microtubule-related genes is due to the interaction of the
CAV-2 fiber with CAR, while the DNA damage response reflects
activation of host DNA-damage repair systems by free viral
DNA ends in the transduced cells. The modest effect on genes
involved in the immune response could also be related to the
immunogenicity of GFP.
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CONCLUSION
Viral vectors will continue to help advance the characterization of
brain function, circuitry and neural plasticity. Our understanding
of the capabilities of CAV-2 vectors, their titers, and cloning
capacity are assets that will allow users to create multiple and/or
complex cassettes under transcriptional or post-translational
control to explore the healthy and diseased brain (Box 2).
Nevertheless, there are caveats. As mentioned above, we do not
know the transduction efficiency of all neuronal types. Because
CAV-2 relies on CAR for uptake and transport, CAR-negative
neurons will be poorly transduced. In another report in this
Research Topic series, Iria Gonzales Dopeso-Reyes will show
that the CAR expression pattern in mice, rats, microcebes and
macaques varies considerably. One way to circumvent the lack of
CAR expression by some neurons is the approach developed by
Li et al. (2018). They used a receptor complementation strategy
via an AAV vector to express CAR in candidate projection
neurons. Exogenous CAR expression mediated by the AAV
vector increased CAV-2 retrograde labeling efficacy. However,
a confounding issue is our rudimentary understanding of the
neuronal functions of CAR. Exogenous expression of CAR, which
can be recruited to activate synapses (Zussy et al., 2016), might
affect neuronal function and downstream cognitive assays.
Another approach to increase CAR-tropic virus infection
is the use of nanovesicles covered with CAR (marketed by
TakaraTM). The CAR-coated nanovesicles fuse with the plasma
membrane of cells to transiently allow CAV-2 attachment and
internalization. Whether the CAR-covered nanovesicles can be
used in the mammalian brain has not been reported. In vivo
use of nanovesicles could create complications because all cells
would likely take up the microvesicles, thereby obviating the
preferential transduction of neurons by CAV-2 vectors. Yet,
neuron-specific transgene expression could be controlled by
using appropriate promoters driving the expression cassette. If
nanovesicles were used to characterize neuronal circuits, the
exogenous CAR would need to be trafficked to distal regions of
the axons. Finally, exogenous CAR could affect neuronal function
and downstream cognitive assays. We found that, after CAR
depletion in the striatum, its replacement takes approximately
2 weeks (Zussy et al., 2016). This suggests, but does not directly
demonstrate, that CAR is relatively stable and its aberrant
expression could have long-term effects on neuron homeostasis.
A third approach is modifying the CAV-2 capsid to
preferentially target neuronal subtypes. Numerous methods have
been developed to modify the tropism of adenoviruses. These
include swapping fiber knobs from other types and adding
ligands into the fiber, penton base, hexon, or protein IX by
inserting a sequence into their open reading frame. Finally,
one could create a “bi-polar” recombinant protein with one
end that binds the fiber knob and the other end that targets
a cell surface moiety. Several reviews describe these and other
approaches (Arnberg, 2012; Yoon et al., 2016; Yamamoto et al.,
2017; Zhang and Ehrhardt, 2017).
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